Sorafenib in Advanced Hepatocellular Carcinoma
Authors:
- Giancarlo SpinziGSGiancarlo Spinzi
- Silvia PaggiSPSilvia Paggi
- 4 December 2008
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 359 (23) , 2497-2499
Abstract
Llovet et al. (July 24 issue)1 report that their study of sorafenib therapy in patients with hepatocellular carcinoma showed a higher overall incidence of treatment-related adverse events with sorafenib than with placebo (80% vs. 52%), although the difference was not noted to be significant. The availability of new therapies, with expected small variations in objective end points, has heightened awareness of the importance of the impact of treatment on patients' overall lives.2 Besides the traditional end points (e.g., median overall survival and time to radiologic progression), quality of life has been acknowledged as an important issue in cancer clinical trials and clinical practice.3,4 We think that an assessment of patients' quality of life would have provided important complementary information to be evaluated in the article.Keywords
This publication has 15 references indexed in Scilit:
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysisThe Lancet Oncology, 2008
- Factores pronósticos en pacientes con carcinoma hepatocelular desestimado para tratamientoGastroenterología y Hepatología, 2007
- 3500 ORAL Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinomaEuropean Journal of Cancer Supplements, 2007
- Chemoresistance of Endothelial Cells Induced by Basic Fibroblast Growth Factor Depends on Raf-1–Mediated Inhibition of the Proapoptotic Kinase, ASK1Cancer Research, 2007
- Quality of life is predictive of survival in patients with unresectable hepatocellular carcinomaAnnals of Oncology, 2006
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Role of Raf in Vascular Protection from Distinct Apoptotic StimuliScience, 2003
- Assessment of Quality of Life During ChemotherapyActa Oncologica, 2001
- The Role of Serum Alpha-Fetoprotein estimation in the Diagnosis and Management of Hepatocellular CarcinomaClinics in Liver Disease, 2001